SB 854, titled the Risky Research Review Act, would create an independent federal board called the Life Sciences Research Security Board to review proposed federal funding for certain high-risk life sciences research before money can be awarded. The bill defines covered research broadly, including dual use research of concern, gain-of-function research, and work involving high-consequence pathogens such as influenza A, coronaviruses in the Sarbecovirus and Merbecovirus subgenera, Ebola, Marburg, Lassa, Nipah, Hendra, Yersinia pestis, select agents and toxins, and related synthetic constructs. The Board would be composed of nine presidential appointees, including scientists, national security experts, and a biosafety expert, and would be led by an Executive Director. It would have authority to issue binding determinations on whether agencies may fund proposed research and to set minimum biosafety, biosecurity, and personnel assurance requirements.
The bill also creates a detailed pre-award and ongoing review process for federal agencies that fund life sciences research. Agencies would have to require applicants to attest whether a proposal is high-risk research and whether they are working with select agents or toxins, notify the Board before awarding funding, and pause or refer research if circumstances change during a project. The Board could review classified information, request additional records, suspend reviewable funding, and audit past federally funded research for compliance. It would also be able to establish scientific expert panels, issue regulations, and report regularly to Congress, while the Government Accountability Office would periodically audit the Board. The bill authorizes $30 million annually for fiscal years 2026 through 2035 and amends federal financial disclosure rules to cover Board members.
If enacted, the bill would significantly expand federal oversight of life sciences research funded by the government, especially research involving pathogens, toxins, or experiments that could increase transmissibility, virulence, immune evasion, or environmental stability. It would add a new layer of centralized review over agencies’ grant, contract, and cooperative agreement decisions and could delay, condition, or block funding for research deemed high-risk. It would also impose new disclosure, reporting, and compliance obligations on researchers, institutions, contractors, and agencies, including requirements tied to subawards, subcontracts, and changes in research circumstances.
The available context shows no recorded committee transcript discussion and no votes, so there is no documented floor or committee sentiment in the provided materials. Based on the bill text alone, the measure appears to be framed as a national security and biosafety safeguard, with an emphasis on preventing misuse of dangerous biological research while preserving a review path for emergency research. The structure of the bill suggests a strong preference for independent oversight and transparency, but the absence of recorded debate means no formal sentiment can be attributed to specific members in the supplied record.
Potential points of contention likely include whether the Board’s authority is too broad or too restrictive, especially because its determinations are binding on agencies and it can review classified research and past funding. Researchers and institutions may object to the breadth of the definitions, the mandatory pauses and reporting requirements, and the possibility of delays to legitimate scientific work, while supporters would likely emphasize biosafety, biosecurity, and national security protections. The bill also raises possible concerns about conflicts of interest, the role of outside experts, and the balance between scientific autonomy and federal control over sensitive research.
SB 854 would amend title 31 of the U.S. Code to add a new Chapter 79 establishing the Life Sciences Research Security Board and would also amend federal financial disclosure law in title 5 to include Board members. It would require federal agencies to route certain life sciences funding proposals through the Board for pre-award review, prohibit funding of high-risk research without Board approval, and create ongoing reporting, disclosure, and compliance duties for agencies and recipients. The bill would affect federal grantmaking, contracting, and cooperative agreement processes across agencies that fund biomedical, biotechnology, genomics, and related research, while adding new oversight, audit, and ethics requirements.
No committee transcript or vote record was provided, so there is no documented legislative sentiment from debate or roll call in the supplied materials. The bill’s text indicates a generally precautionary, security-focused approach that seeks to prevent dangerous biological research from being federally funded without independent review, suggesting support from lawmakers concerned about biosafety and national security. At the same time, the breadth and binding nature of the review regime suggest the measure could draw concern from research stakeholders worried about delays, administrative burden, and limits on scientific discretion.
The main likely point of contention is the scope of the Board’s authority: it can make binding funding determinations, review classified research, and define additional categories of high-risk research by majority vote, which some may view as overly expansive. Another likely dispute is the breadth of the underlying definitions, especially the inclusion of gain-of-function research, dual use research of concern, and a wide list of pathogens and toxins, which could capture a large range of legitimate research. Researchers, universities, and agencies may also object to the bill’s mandatory attestations, pause requirements, disclosure of subawards and subcontracts, and potential suspension or debarment consequences, while supporters are likely to argue these safeguards are necessary to reduce biosafety and biosecurity risks.